Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. (2017)
Attributed to:
Biomedical Catalyst – Drug product production, clinical support studies, and phase 1 trial of a new MS drug
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.msard.2017.01.007
PubMed Identifier: 28283111
Publication URI: http://europepmc.org/abstract/MED/28283111
Type: Journal Article/Review
Volume: 12
Parent Publication: Multiple sclerosis and related disorders
ISSN: 2211-0348